Publicacions - Fundació Institut d'Investigació en Ciències de la
Publicacions - Fundació Institut d'Investigació en Ciències de la
Publicacions - Fundació Institut d'Investigació en Ciències de la
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
1: a substudy of the TIBET trial<br />
AIDS 2010<br />
IF: 6,348<br />
Fr<strong>en</strong>tz D, Boucher CA, Assel M, De Luca A, Fabbiani M, Incardona F, Libin P, Manca N, Müller V, O<br />
Nualláin B, Pare<strong>de</strong>s R, Prosperi M, Quiros-Roldan E, Ruiz L, Sloot PM, Torti C, Vandamme AM, Van<br />
Laethem K, Zazzi M, van <strong>de</strong>Vijver DA.<br />
Comparison of HIV-1 g<strong>en</strong>otypic resistance test interpretation systems in predicting virological outcomes<br />
over time.<br />
PLOS ONE 2010 Jul 9;5(7):e11505<br />
IF: 4,411<br />
Friis-Møller N, Thiébaut R, Reiss P, Weber R, Monforte AD, De Wit S, El-Sadr W, Fontas E, Worm S, Kirk<br />
O, Phillips A, Sabin CA, Lundgr<strong>en</strong> JD, Law MG; DAD study group. (R. Pare<strong>de</strong>s as member of the EuroSIDA<br />
Study Group)<br />
Predicting the risk of cardiovascu<strong>la</strong>r disease in HIV-infected pati<strong>en</strong>ts: the data collection on adverse<br />
effects of anti-HIV drugs study<br />
EUR J CARDIOV PREV R 2010 Oct;17(5):491-501<br />
IF: 2,633<br />
Garcia-Prado J, Pr<strong>en</strong><strong>de</strong>rgast A, Thobakgale C, Molina C, Tudor-Williams G, Ndung'u T, Walker BD,<br />
Goul<strong>de</strong>r P.<br />
Replicative capacity of human immuno<strong>de</strong>fici<strong>en</strong>cy virus type 1 transmitted from mother to child is<br />
associated with pediatric disease progression rate.<br />
J VIROL 2010 Jan;84(1):492-502. Epub .<br />
IF: 5,189<br />
Gatell JM, Kat<strong>la</strong>ma C, Grinsztejn B, Eron JJ, Lazzarin A, Vittecoq D, Gonzalez CJ, Danovich RM, Wan H,<br />
Zhao J, Meibohm AR, Strohmaier KM, Harvey CM, Isaacs RD, Nguy<strong>en</strong> BY; Protocol 005 Team. (B<strong>la</strong>nco J,<br />
Clotet B in col<strong>la</strong>borators)<br />
Long-term efficacy and safety of the HIV integrase inhibitor raltegravir in pati<strong>en</strong>ts with limited treatm<strong>en</strong>t<br />
options in a Phase II study.<br />
JAIDS-J ACQ IMM DEF 2010 Apr 1;53(4):456-63.<br />
IF: 4,262<br />
González-Ortega E, M<strong>en</strong>a MP, Permanyer M, Bal<strong>la</strong>na E, Clotet B, Esté JA.<br />
ADS-J1 inhibits HIV-1 <strong>en</strong>try by interacting with gp120 and does not block the fusion-active gp41 core<br />
formation.<br />
ANTIMICROB AGENTS CH 2010 Oct;54(10):4487-92. Epub 2010 Jul 19<br />
IF: 4,672<br />
Gonzalez, E., M. P. M<strong>en</strong>a, M. Armand-Ugon, E. Bal<strong>la</strong>na, B. Clotet, and J. Este. 2010.<br />
Developm<strong>en</strong>t of Resistance to the Natural HIV-1 Entry Virus Inhibitory Pepti<strong>de</strong> (VIRIP)<br />
ANTIVIR RES 2010.02.375|65<br />
IF: 4,439<br />
Hill AM, Clotet B, Johnson M, Stoll M, Bellos N, Smets E.<br />
Costs to Achieve Un<strong>de</strong>tectable HIV RNA with Darunavir-Containing Highly Active Antiretroviral Therapy<br />
in Highly Pretreated Pati<strong>en</strong>ts: The POWER Experi<strong>en</strong>ce.<br />
PHARMACOECONOMICS 2010 Dec 23;28 Suppl 1:69-81. doi: 10.2165/11587460-000000000-00000.<br />
IF: 3,44<br />
Pàgina 51 <strong>de</strong> 148
Change language